+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Apoptosis Assay Market - Growth, Trends, and Forecasts (2020 - 2025)

  • PDF Icon


  • 112 Pages
  • June 2020
  • Region: Global
  • Mordor Intelligence
  • ID: 4896188
The major factors attributing to the growth of the apoptosis assay market are the rising incidence of infectious and chronic diseases such as autoimmune diseases, cancer, and others. Rise in population suffering from chronic and autoimmune diseases are propelling the demand for market growth. In 2018, as per the AARDA (AMERICAN AUTOIMMUNE RELATED DISEASE ASSOCIATION) statistics, around 50 million Americans have an autoimmune disease, and this number is expected to rise in the future. And there are few more factors which are playing crucial roles in taking the apoptosis assay market to the next level, among them one is on-going developments related to apoptosis-modulating drugs which are expected to further propel the growth of the global apoptosis assays market. However, Increasing demand for high-content diagnosis and clinical research for cancer, in particular, is indeed bolstering market growth during the forecasted period.

Key Market Trends

Assay Kits Segment is Expected to Hold the Largest Market Share in the Apoptosis Assay Market
  • Assay kits identify and quantify cell events related to programmed cell death, involving caspase initiation, phosphatidylserine (PS) cell surface exposure and DNA fragmentation.
  • The number of repetitive consumption of assay in numerous other apoptosis processes can propel the demand of the assay kits during the forecast period.
  • The rising incidence of infectious and chronic diseases such as autoimmune diseases, cancer, and others is also boosting the market growth. As per the statistics from GLOBOCAN 2018, worldwide 18,078,957 individuals have cancer. Asia remains the leading contributor in the rising incidence of cancer with a reported share of 48.4% followed by Europe, North and Latin America, Africa, and Oceania with a share of 23.4%, 13.2% and 7.8%, 5.8%, and 1.4% respectively.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall apoptosis assay market, throughout the forecast period. This is owing to the factors such as the rising incidence of chronic diseases such as cancer and the availability of advanced healthcare infrastructure among the major factors. In North America region, the United States holds the largest market share owing to the factors such as increasing number of population suffering from autoimmune diseases and chronic disease, along with the rising geriatric population and developments related to apoptosis-modulating drugs in the country, is anticipated to stimulate the demand in this region.

Competitive Landscape

The apoptosis assay market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Ans some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Thermo Fisher Scientific, Bio-Rad Laboratories, Merck KGaA, GE Healthcare, and Becton, Dickinson and Company.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Chronic and Autoimmune Diseases
4.2.2 Developments Related to Apoptosis-Modulating Drugs
4.3 Market Restraints
4.3.1 Stringent Regulatory Reforms
4.3.2 Expensive Detection Technology and High Capital Investment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Assay Kits Annexin V Caspase Assay Others
5.1.2 Reagents
5.1.3 Instruments
5.1.4 Microplates
5.2 By Detection Technology
5.2.1 Spectrophotometry
5.2.2 Flow Cytometry
5.2.3 Cell Imaging and Analysis Systems
5.2.4 Other Technology
5.3 By Application
5.3.1 Stem Cell Research
5.3.2 Clinical and Diagnostics Application
5.3.3 Drug Discover and Development
5.3.4 Others
5.4 By End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Hospitla and Laboratories
5.4.3 Academic and Research Institutes
5.5 Geography
5.5.1 North America United States Canada Mexico
5.5.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.5.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.5.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific
6.1.2 Merck KGaA
6.1.3 Bio-Rad Laboratories
6.1.4 GE Healthcare
6.1.5 Becton, Dickinson and Company
6.1.6 Sartorius AG
6.1.7 GeneCopoeia, Inc.
6.1.8 BioTek Instruments
6.1.9 Bio-Techne Corporation
6.1.10 PerkinElmer Inc.
6.1.11 Promega Corporation

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific
  • Merck KGaA
  • Bio-Rad Laboratories
  • GE Healthcare
  • Becton, Dickinson and Company
  • Sartorius AG
  • GeneCopoeia, Inc.
  • BioTek Instruments
  • Bio-Techne Corporation
  • PerkinElmer Inc.
  • Promega Corporation